Sheraton Centre Toronto
Grand West Room
123 Queen Street West
Toronto, ON M5H 2M9, Canada
5:30 AM: Registration and Breakfast
6:00 AM: Welcome and Introduction (Dr. Flaherty)
6:05 AM: Improving Differential Diagnosis of Interstitial Lung Disease (Dr. Flaherty)
6:20 AM: Informed Treatment Decisions in Idiopathic Pulmonary Fibrosis (Dr. Lancaster)
6:35 AM: What’s on the Horizon? Update on Therapeutic Trials for IPF and Other Progressive Fibrosing Lung Diseases (Dr. Martinez)
6:50 AM: Q&A, Reflection, and Conclusions (Dr. Flaherty and faculty panel)
In this live symposium, a panel of experts in pulmonology will discuss how to distinguish between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) based on unique radiographic and pathologic features. The panel will review clinical data and emerging regimens for IPF and progressive fibrosing ILD, and provide guidance on how to apply evidence-based recommendations to obtain an accurate diagnosis and optimize treatment of ILD in your clinical practice.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of pulmonologists and other clinicians involved in the management of patients with ILD.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.
Release and Expiration Date: Monday, October 30, 2017
Time to Complete: 60 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
Kevin R. Flaherty, MD, MS
Professor of Medicine
Department of Pulmonary & Critical Care
University of Michigan Health System
Ann Arbor, Michigan
Lisa H. Lancaster, MD
Medical Director Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis Program
Associate Professor of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York
Chris Washburn, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.